Skip to main content

Branded

  • Teva receives FDA nod for QVAR

    JERUSALEM — Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in patients 5 years of age and older.

    The counter will help asthma patients and their caregivers keep track of the number of remaining doses in the canister. It will be commercially available later this year, according to the company.

  • Surescripts routes record 1 billion-plus electronic prescriptions in 2013

    ARLINGTON, Va. — Surescripts on Wednesday announced its service has routed more than 1 billion electronic prescriptions in 2013, representing a majority (58%) of all eligible prescriptions in the United States, sent by 73% of all office-based physicians.  

  • Takeda's Entyvio approved to treat moderately to severely active ulcerative colitis and Crohn's disease

    DEERFIELD, Ill. — Takeda Pharmaceutical on Tuesday announced that the Food and Drug Administration simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

  • JAMA: Low-income families with high cost-share levels most likely to forego a child's asthma treatment

    CHICAGO — According to a report published Monday by JAMA Pediatrics, cost-related barriers to care among children with asthma are concentrated among low-income families with higher cost-sharing levels.

  • Practice Fusion launches real-time healthcare database Insight

    SAN FRANCISCO — Practice Fusion on Wednesday launched its real-time healthcare database, Insight. With Insight, physicians, researchers and analysts can access analysis sourced from a de-identified subset of more than 81 million patient records. Insight users can explore health and pharmaceutical market trends, including diagnoses across patient populations, all in real-time.

    Offered free of charge, Insight is designed to provide a full perspective across the healthcare spectrum, from diagnosis to treatment, that can identify new research opportunities and market trends.

  • AstraZeneca rejects Pfizer's final bid of $118 billion

    NEW YORK — Pfizer on Sunday made a final offer valued at $118 billion for AstraZeneca. AstraZeneca, in turn, rejected the bid Monday morning. 

  • Pfizer to submit NDA for palbociclib

    NEW YORK — Pfizer announced plans to submit a new drug application with the Food and Drug Administration for palbociclib (combined with letrozole). The drug is used for the first-line systemic treatment of post-menopausal women with advanced or metastatic breast cancer.

    The company said it plans to submit the NDA early in third quarter 2014. The decision to file was based on discussions with the FDA surrounding the final results of a randomized, Phase 2 trial called PALOMA-1.

     

  • FDA lowers current recommended starting dosage on Rx sleep remedy Lunesta

    SILVER SPRING, Md. — The Food and Drug Administration on Thursday announced it required Sunovion Pharmaceuticals, manufacturer of the sleep drug Lunesta (eszopiclone), to change the drug label and lower the current recommended starting dose. Data show that eszopiclone levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving, even if they feel fully awake.

X
This ad will auto-close in 10 seconds